Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer

Background Extracellular vesicles (EVs) are small nanometre-sized vesicles that are circulating in blood. They are released by multiple cells, including tumour cells. We hypothesized that circulating EVs contain protein kinases that may be assessed as biomarkers during treatment with tyrosine kinase inhibitors. Methods EVs released by U87 glioma cells, H3255 and H1650 non-small-cell lung cancer (NSCLC) cells were profiled by tandem mass spectrometry. Total AKT/protein kinase B and extracellular signal regulated kinase 1/2 (ERK1/2) levels as well as their relative phosphorylation were measured by western blot in isogenic U87 cells with or without mutant epidermal growth factor receptor (EGFRvIII) and their corresponding EVs. To assess biomarker potential, plasma samples from 24 healthy volunteers and 42 patients with cancer were used. Results In total, 130 different protein kinases were found to be released in EVs including multiple drug targets, such as mammalian target of rapamycin (mTOR), AKT, ERK1/2, AXL and EGFR. Overexpression of EGFRvIII in U87 cells results in increased phosphorylation of EGFR, AKT and ERK1/2 in cells and EVs, whereas a decreased phosphorylation was noted upon treatment with the EGFR inhibitor erlotinib. EV samples derived from patients with cancer contained significantly more protein (p=0.0067) compared to healthy donors. Phosphorylation of AKT and ERK1/2 in plasma EVs from both healthy donors and patients with cancer was relatively low compared to levels in cancer cells. Preliminary analysis of total AKT and ERK1/2 levels in plasma EVs from patients with NSCLC before and after sorafenib/metformin treatment (n=12) shows a significant decrease in AKT levels among patients with a favourable treatment response (p<0.005). Conclusion Phosphorylation of protein kinases in EVs reflects their phosphorylation in tumour cells. Total AKT protein levels may allow monitoring of kinase inhibitor responses in patients with cancer.

[1]  A. von Deimling,et al.  BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma , 2013, British Journal of Cancer.

[2]  Hakho Lee,et al.  Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy , 2012, Nature Medicine.

[3]  John V Heymach,et al.  Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. , 2012, The Lancet. Oncology.

[4]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[5]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[6]  Tobias Meyer,et al.  Supplemental Experimental Procedures A Two-Dimensional ERK-AKT Signaling Code for an NGF-Triggered Cell-Fate Decision , 2011 .

[7]  T. Wurdinger,et al.  Blood platelets contain tumor-derived RNA biomarkers. , 2011, Blood.

[8]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.

[9]  Hamid Cheshmi.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[10]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11]  S. Hilsenbeck,et al.  Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Bertina,et al.  Pre-analytical and analytical issues in the analysis of blood microparticles , 2010, Thrombosis and Haemostasis.

[13]  Henk M. W. Verheul,et al.  Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods , 2010, Analytical and bioanalytical chemistry.

[14]  R. Bernards.  It's Diagnostics, Stupid , 2010, Cell.

[15]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[16]  Connie R. Jimenez,et al.  On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics , 2010, Bioinform..

[17]  Ultan McDermott,et al.  Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. D. Van den Abbeele,et al.  Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure , 2009, Clinical Cancer Research.

[19]  Xin Huang,et al.  Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure , 2009, Clinical Cancer Research.

[20]  M. Rubin,et al.  Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. , 2009, Cancer research.

[21]  Jacopo Meldolesi,et al.  Shedding microvesicles: artefacts no more. , 2009, Trends in cell biology.

[22]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[23]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[24]  B. Calvo,et al.  Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[26]  M. Mann,et al.  Is Proteomics the New Genomics? , 2007, Cell.

[27]  R. Gray,et al.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. , 2007, Journal of the National Cancer Institute.

[28]  J. Baselga,et al.  Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[30]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[31]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[32]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[33]  Graça Raposo,et al.  The Biogenesis and Functions of Exosomes , 2002, Traffic.

[34]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[35]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[36]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .